

Press Release

Basel, 28. February 2012

New MultiCyt™ Screening Kits for Biologics Discovery

IntelliCyt HTFC™ High Throughput Flow Cytometry Screening System

IntelliCyt Corporation, a leading life science technology provider of innovative high-throughput cell-based screening solutions, has launched a unique suite of screening kits to address the rapidly growing biologics market. The new MultiCyt Screening Kits, used with the HTFC® Screening System which combines high sensitivity with single cell measurements, address challenges and limitations associated with legacy platforms.



The **MultiCyt Hybridoma Screening Kit** is a powerful, mix-and-measure solution for primary screening of hybridoma libraries, designed to test antibody binding directly on living cells. This high-throughput solution allows scientists to detect antibodies that bind to unique conformational epitopes that may be missed with current ELISA assays.

The **MultiCyt Count and Capture - IgG Secretion Screening Kit** is a novel multiplexed screening assay that provides a single platform solution for researchers assessing productivity of antibody-secreting cell lines. By simultaneously measuring the amount of secreted protein and providing a viable cell count, the amount of antibody produced can be determined on a per-cell basis in one assay, saving valuable time and resources in the cell line generation process.

The **MultiCyt Cell Encoder Screening Kit** enables multiple cell lines to be color coded and combined into screening plates to test target-specific clone binding characteristics and select those with the greatest promise for pre-clinical and clinical trials. Using the HTFC Screening System, the cell lines are combined and tested within the same wells, enabling scientists to simultaneously analyze the biology of each encoded cell line.

The IntelliCyt approach to screening assays addresses the need to obtain more answers with smaller amounts of sample. By using far less sample than current methods, coupled with more information, the IntelliCyt assay kits, in conjunction with the HTFC platform, achieve significant productivity increases and provide better decision-making capabilities. "Our technology provides a valuable solution to the therapeutic antibody community by answering multiple questions on a single platform, addressing bottlenecks resulting from repetitive screening testing on multiple platforms, as well as reducing costs and improving time to results. Our technology will redefine what users can accomplish from their screening campaigns," said R. Terry Dunlay, CEO of IntelliCyt.

Interested in a system Demo? Simply give us a call!

Bucher Biotec AG

Viaduktstrasse 42
4051 Basel

Tel.: 061 269 1111
Fax: 061 269 1112

Email: info@bucher.ch
www: <http://www.bucher.ch>